NOW AVAILABLE!

What is the OLUX® Foam/OLUX-E® Foam Complete Pack?

It's 2 different medications proven to treat your dermatoses in
1 pack—all for 1 co-pay.

  1. OLUX® (clobetasol propionate) Foam:
    • Reduces redness, itching, and flaking
    • Easy to apply
    • Contains alcohol

  2. OLUX-E® (clobetasol propionate) Foam:
    • Reduces redness, itching, and flaking
    • Soothes skin
    • Easy to apply
    • No ethanol (alcohol)

How do I know when to use OLUX® (clobetasol propionate) Foam and when to use OLUX-E® (clobetasol propionate) Foam?


Always follow your doctor's instructions about how to use OLUX® Foam and OLUX-E® Foam. Your doctor will be able to tell you when and where you should apply each medication.

The convenient OLUX® Foam/OLUX-E® Foam Complete Pack lets you treat dermatoses on your body or on your scalp.

OLUX® Foam is made with VERSAFOAM-HF® Foam, an alcohol based formulation. OLUX-E® Foam is made with VERSAFOAM-EF® Foam, which does not contain alcohol and has a soothing feel.

Treatment with OLUX® Foam or OLUX-E® Foam beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for suppression of the hypothalamic-pituitary-adrenal (HPA) axis.




StiefelCareSM Insurance Reimbursement Program Value
  • Provides financial reimbursement for those who are eligible
  • Call (800) 572-3225. Monday-Friday 8:00 AM to 8 PM Eastern Time

IMPORTANT SAFETY INFORMATION

OLUX® Foam is indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of non-scalp regions excluding the face and intertriginous areas. OLUX® Foam is not recommended for use in children under 12 years of age.

In clinical trials, the most common adverse events associated with the use of OLUX® Foam were burning, dryness, and other reactions at the application site.

OLUX-E® Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older.

The pooled incidence of local adverse reactions in trials for moderate to severe atopic dermatitis and mild to moderate plaque-type psoriasis with OLUX-E® Foam was 1.9%for application site atrophy and 1.6% for application site reaction.

Please see accompanying full Prescribing Information for OLUX® Foam and OLUX-E® Foam.

The Foam Dollop Design is a trademark, and STIEFEL, STIEFEL & Design, the V Design, OLUX, OLUX-E, OLUX-E & Design, VERSAFOAM, VERSAFOAM-HF, and VERSAFOAM-EF are registered trademarks of Stiefel Laboratories, Inc.

STIEFELCARE and STIEFELCARE & Design are service marks of Stiefel Laboratories, Inc.

Rebate Offer

Instantly save up to $35 off your OLUX® Foam prescription (even works with copay).

learn more

Patient Information Brochure

Download this helpful patient information brochure to learn more about OLUX® Foam and scalp dermatoses.

download